Literature DB >> 30809949

Sex hormone replacement therapy for individuals with Turner syndrome.

Philippe Backeljauw1, Karen Klein2.   

Abstract

Turner syndrome is a relatively common genetic condition resulting from absence of all or part of the second sex chromosome. Individuals with Turner syndrome commonly exhibit cardiovascular, endocrine, renal, reproductive, and/or psychosocial abnormalities, among other conditions. Most girls with Turner syndrome have hypergonadotropic hypogonadism and therefore need sex steroid hormonal replacement therapy. The optimal estrogen replacement treatment regimen to induce pubertal development is still being determined. The goals of the estrogen replacement are to mimic the normal physical and social development for timing and progression of puberty. Treatment should begin at 11-12 years of age, with dose increases every 6 months over a 2-3 year period. Initiation with low doses of estrogen is crucial to preserve growth potential. On the other hand, delaying estrogen replacement may be deleterious to bone and uterine health.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  estrogen; ovarian failure; turner syndrome

Mesh:

Year:  2019        PMID: 30809949     DOI: 10.1002/ajmg.c.31685

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  3 in total

1.  Brain Development in School-Age and Adolescent Girls: Effects of Turner Syndrome, Estrogen Therapy, and Genomic Imprinting.

Authors:  Stefani O'Donoghue; Tamar Green; Judith L Ross; Joachim Hallmayer; Xiaoyan Lin; Booil Jo; Lynne C Huffman; David S Hong; Allan L Reiss
Journal:  Biol Psychiatry       Date:  2019-08-09       Impact factor: 13.382

Review 2.  The Care of Adolescents and Young Adults with Turner Syndrome: A Pediatric and Adolescent Gynecology Perspective.

Authors:  Tazim Dowlut-McElroy; Roopa Kanakatti Shankar
Journal:  J Pediatr Adolesc Gynecol       Date:  2022-03-08       Impact factor: 2.046

Review 3.  Endocrine Disorder in Patients With Craniopharyngioma.

Authors:  Zihao Zhou; Sheng Zhang; Fangqi Hu
Journal:  Front Neurol       Date:  2021-12-02       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.